INTRODUCTION {#s1}
============

Depression is a severe mental health disorder developed under different circumstances, formally diagnosed by DSM-IV or DSM-V (Diagnostic and Statistical Manual of Mental Disorders 4^th^ edition or 5^th^ edition) \[[@R1], [@R2]\]. Depressive symptoms, such as fatigue, loss of interest, decreased energy, feelings of guilt, worthlessness could be main manifestations of depressive disorder or other psychological diseases \[[@R1], [@R2]\]. Depression or depressive symptoms among brain tumor patients have been reported by distinct diagnostic clinical interviews with distinct criteria and thresholds \[[@R3], [@R4]\], which have been linked to the adverse course of the disease, a worsened life quality and even higher rates of mortality \[[@R4]--[@R8]\]. However, estimates of the prevalence of depression or depressive symptoms varied greatly, ranging from 2.8% to 95% \[[@R9], [@R10]\]. Different screening and diagnostic scales were employed to evaluate depression prevalence in brain tumor patients with different age or sex, education level, countries, brain tumor type and grade, thus leading to various findings about the estimated depression prevalence \[[@R11]--[@R14]\].

The adverse impacts of depression or depressive symptoms among patients with brain tumor, the various risk factors and the variations between assessment tools, have made it an urgent task to obtain an accurate and reliable depression prevalence in brain tumor patients. The aim of our study is to acquire a proper summary estimate of the depression prevalence and to discuss the reasonable and suitable depression assessment instruments in the clinical setting. Therefore, we conducted a systematic review and meta-analysis from 37 observational studies, to get a summary prevalence of depression among brain tumor patients and help to develop a better identification, prevention and treatment of the depression co-morbidity and original tumor.

RESULTS {#s2}
=======

Selection of studies and study characteristics {#s2_1}
----------------------------------------------

The initial search strategy identified 2746 potentially articles: 2615 from PUBMED, 73 from Cochrane library, and 58 from PsycINFO. Figure [1](#F1){ref-type="fig"} presented details of the studies included in the meta-analysis. After screening the titles and abstracts according to the selection criteria, we excluded 2622 studies. We also identified additional studies by reference scanning and previous meta-analysis or reviews. Overall, we got a total of 37 eligible studies for further analysis.

![Meta-analysis flowchart for identifying studies on the prevalence of depression among brain tumor patients](oncotarget-08-94932-g001){#F1}

Main associations of depression with brain tumor {#s2_2}
------------------------------------------------

These studies provided a total sample of 4518 patients (median sample size = 122 patients, range = 22--573 patients) including 25 cross-sectional \[[@R4], [@R5], [@R12], [@R14], [@R19], [@R22]--[@R24], [@R33]--[@R49]\] studies, 12 longitudinal studies \[[@R6], [@R7], [@R13], [@R20], [@R21], [@R50]--[@R56]\]. No randomized controlled trial was eligible. All 37 studies are prospective research. The average percentage of men in the total sample was 51.3%. 17 studies assessed for depression or depressive symptoms using Hospital Anxiety and Depression Scale (HADS-D) \[[@R4], [@R7], [@R13], [@R14], [@R21], [@R33], [@R35], [@R39]--[@R43], [@R45], [@R46], [@R49]--[@R51]\], 6 used Beck Depression Inventory (BDI) \[[@R5], [@R6], [@R23], [@R44], [@R52], [@R54], [@R57]\], 2 used the Zung Self-Rating Depression Scale (Zung SDS) \[[@R51], [@R58]\], 2 used Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition (DSM-IV) \[[@R12], [@R47]\], 10 used other methods \[[@R19], [@R20], [@R22], [@R24], [@R34], [@R36], [@R37], [@R48], [@R53], [@R56]\]. The diagnostic criteria used by the studies were summarized in Table [1](#T1){ref-type="table"}. When evaluated by the modified Newcastle-Ottawa scale, out of 5 possible points, 0 studies received 5 points, 6 received 4 points, 18 received 3 points, 9 received 2 points, 4 received 1 point, and 0 received 0 points (detailed criteria were presented in the [Supplementary 2](#SD3){ref-type="supplementary-material"}).

###### Characteristics of studies included in this systematic review and meta-analysis

  First author   Year   Country       Study design      Recuitment    Patients, n   Male patients, n (%)   Age, y, mean   Brain tumor type    WHO low-grade, n   WHO high-grade, n   Surgery,%   Education≥high school,%   Married, %   Previous psychiatric illness,%   White,%   Depression scale
  -------------- ------ ------------- ----------------- ------------- ------------- ---------------------- -------------- ------------------- ------------------ ------------------- ----------- ------------------------- ------------ -------------------------------- --------- -----------------------
  Hickmann       2016   Switzerland   Longitudinal      Prospective   83            43.4                   51.9           multiple            51                 31                  98.8        30                        NR           NR                               NR        BDI
  Jenkins        2015   Australia     cross-sectional   Prospective   33            NR                     45.75          multiple            0                  30                  NR          NR                        NR           NR                               NR        HADS-D
  WELLISCH       2002   USA           cross-sectional   Prospective   89            55                     43.2           multiple            NR                 39                  73          67.1                      61.8         15.8                             NR        DSM-IV
  Arnold         2008   USA           cross-sectional   Prospective   363           58                     43.7           multiple            219                144                 NR          83                        76           5                                95        PHQ-9
  Anderson       1999   UK            cross-sectional   Prospective   40            60                     44             glioma              24                 16                  83          NR                        70           NR                               NR        HDS
  Davies         1996   UK            Longitudinal      Prospective   75            69                     NR             multiple            0                  75                  NR          NR                        78           NR                               93        open ended interviews
  Pringle        1999   UK            cross-sectional   Prospective   109           56.88                  NR             multiple            53                 32                  93          NR                        NR           NR                               NR        HADS-D
  Litofsky       2004   USA           Longitudinal      Prospective   573           58                     55             glioma              0                  598                 81.4        NR                        80           NR                               92.5      SF-36
  Pelletier      2002   Canada        cross-sectional   Prospective   58            51.67                  41.1           multiple            18                 34                  90          95                        66.6         NR                               NR        BDI-II
  Edelstein      2015   USA           cross-sectional   Prospective   73            60.3                   NR             glioma              0                  73                  NR          NR                        83.6         NR                               NR        CES-D
  Wenz           2015   Germany       cross-sectional   Prospective   58            72.2                   62.6           meningioma          58                 0                   77.9        NR                        NR           20.83                            NR        BCS
  Piil           2015   Denmark       Longitudinal      Prospective   28            63.3                   60             glioma              0                  30                  76.67       NR                        80           NR                               NR        HADS-D
  Rahman         2015   Australia     cross-sectional   Prospective   81            58                     NR             multiple            30                 51                  100         58                        NR           NR                               NR        HADS-D
  Leistner       2015   Germany       cross-sectional   Prospective   247           37                     53.25          pituitary adenoma   0                  0                   66.7        NR                        NR           NR                               NR        BDI
  Lucchiari      2014   Italy         cross-sectional   Prospective   73            66                     48.9           glioma              0                  73                  NR          17.8                      NR           NR                               NR        HADS-D
  Janda          2007   Australia     cross-sectional   Prospective   75            45.9                   74.6           multiple            31                 44                  NR          70.2                      62.2         NR                               NR        HADS-D
  Vossen         2014   Netherlands   cross-sectional   Prospective   136           22                     59.1           meningioma          134                2                   71          40                        NR           NR                               NR        HADS-D
  ANGELO         2008   Italy         Longitudinal      Prospective   72            43.1                   NR             multiple            22                 10                  NR          13.9                      79.17        NR                               NR        Zung SDS
  Bunevicius     2012   Lithuania     Longitudinal      Prospective   226           31                     55.6           multiple            3                  65                  NR          NR                        NR           7.1                              NR        HADS-D
  Andrewes       2013   Australia     cross-sectional   Prospective   32            43.8                   52             multiple            0                  29                  NR          43.8                      NR           NR                               NR        HADS-D
  Goebel         2012   Germany       Longitudinal      Prospective   76            33                     54.42          meningioma          52                 24                  100         NR                        84           11.8                             NR        HADS-D
  Keeling        2012   UK            cross-sectional   Prospective   74            46                     38.3           multiple            64                 0                   68.66       NR                        NR           NR                               NR        HADS-D
  Goebel         2012   Germany       cross-sectional   Prospective   172           48.8                   52.4           multiple            93                 78                  NR          NR                        NR           NR                               NR        HADS-D
  Santini        2012   Italy         Longitudinal      Prospective   22            45                     NR             multiple            14                 8                   100         NR                        NR           NR                               NR        BDI
  Mainio         2006   Finland       Longitudinal      Prospective   77            38.6                   NR             glioma              16                 15                  NR          NR                        NR           NR                               NR        BDI
  Kilbride       2007   UK            Longitudinal      Prospective   51            54.9                   55             multiple            3                  42                  100         NR                        NR           NR                               NR        HADS-D
  Rooney         2011   UK            Longitudinal      Prospective   155           57.4                   NR             glioma              22                 133                 74.8        NR                        80           18.06                            NR        DSM-IV
  Goebel         2011   Germany       cross-sectional   Prospective   180           48.3                   52.7           multiple            NR                 78                  NR          NR                        75.6         NR                               NR        HADS-D
  Armstrong      2002   USA           Longitudinal      Prospective   57            NR                     40.77          glioma              57                 0                   67          NR                        NR           NR                               NR        BDI
  Brown          2006   USA           cross-sectional   Prospective   185           65.5                   NR             glioma              0                  185                 83.5        NR                        NR           NR                               NR        POMS-SF
  CHANG          2003   USA           cross-sectional   Prospective   499           55.7                   NR             glioma              0                  499                 91.8        NR                        NR           NR                               NR        Physician report
  Giovagnoli     1996   Italy         cross-sectional   Prospective   125           101                    60             multiple            NR                 11                  90          NR                        NR           70                               NR        NR
  Grant          1994   UK            cross-sectional   Prospective   48            NR                     NR             glioma              NR                 NR                  NR          NR                        NR           NR                               NR        HADS-D
  Kaplan         2000   USA           cross-sectional   Prospective   33            NR                     33             multiple            0                  33                  NR          NR                        75.8         NR                               NR        BDI
  McGovern       2003   USA           cross-sectional   Prospective   33            NR                     NR             multiple            0                  33                  NR          NR                        NR           NR                               NR        Inpatient notes
  Rooney         2009   UK            cross-sectional   Prospective   100           55                     NR             glioma              NR                 NR                  NR          NR                        NR           NR                               NR        GP records
  Goebel         2010   Germany       cross-sectional   Prospective   150           43.3                   53.15          multiple            73                 77                  NR          NR                        64.3         NR                               NR        HADS-D

BDI, Beck Depression Inventory; HADS-D, Depression Subscale of Hospital Anxiety and Depression Scale; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition; PHQ-9; Patient Health Questionnaire--9; HDS, Hamilton Rating Scale for Depression; SF-36, 36-Item Short Form Health Survey; BDI-II, Beck Depression Inventory-II; CES-D, Center for Epidemiologic Studies-Depression Scale; BCS, Brief Cope Scale; Zung SDS, Zung Self-rating Depression Scale; POMS-SF, Profiles of Mood States Short Form; GP, General Practitioner (family physician); SF-36, 36-Item Short Form Health Survey; NR, not applicable.

First, we compared depression prevalence in the overall sample. Random-effects meta-analysis was performed. And the results showed that the pooled prevalence of depression disorder in brain tumor patients was 21.7% (971/4518 individuals, 95 % confidence interval (CI) 18.2%--25.2%) in the overall sample (Figure [2](#F2){ref-type="fig"}). Significant evidence of between-study heterogeneity was observed in the meta-analysis (I^2^ = 89.3%, P \<0.01). The results of sensitivity analysis were not influenced by an individual study by more than 1% ([Supplementary 3](#SD4){ref-type="supplementary-material"}).

![Forest plot for random-effects meta-analysis showing pooled prevalence of depression in overall sample](oncotarget-08-94932-g002){#F2}

Subgroup analysis {#s2_3}
-----------------

We next compared the prevalence of depression or depressive symptoms depending on different demographic groups, depression scales and other characteristics by a series of sub-group analyses (Table [2](#T2){ref-type="table"} and [Supplementary 4](#SD5){ref-type="supplementary-material"}). No significant differences were observed between studies stratified by cross-sectional vs longitudinal studies (696/3131, 20.7% \[95% CI, 16.2% to 25.2%\] vs 275/1387, 24.0% \[95% CI, 18.1% to 29.8%\]; test for subgroup differences, Q =0.58, P =0.45), tumor types investigated including glioma only vs multiple tumor types such as glioma, meningioma, pituitary adenoma (340/1908, 19.6% \[95% CI, 15.6% to 23.5%\] vs (631/2610, 22.5% \[95% CI, 17.4% to 27.6%\]; Q = 2.89, P = 0.09). Heterogeneity was partly explained by large sample size (sample ≥100) vs small sample size (sample \<100) (668/3273, 19.1% \[95% CI, 13.9% to 24.3%\] vs 303/1245, 23.8% \[95% CI, 19.2% to 28.4%\]); Q = 9.18, P \<0.01), countries patients recruited (studies in the United States vs UK vs Germany vs Italy vs elsewhere (420/1899, 24.3% \[95% CI, 16.9% to 31.7%\] vs 119/831, 14.8% \[95% CI, 10.1% to 19.6%\] vs 132/510, 16.6% \[95% CI, 4.2% to 29.1%\] vs 68/344, 21.7% \[95% CI, 10.9% to 32.4%\] vs 232/934, 27.7% \[95% CI, 20.4% to 35.1%\]; Q = 33.01, P ≤0.01)). Significant prevalence difference between high grade glioma (WHO I and II) vs low grade glioma (WHO III and IV) was also detected (48/418, 19.5% \[95% CI, 13.9% to 25.1%\] vs 180/1133, 15.4% \[95% CI, 6.4% to 24.4%\]; Q = 16.57, P \<0.01) ([Supplementary 5](#SD1){ref-type="supplementary-material"}).

###### Meta-analyses of the prevalence of depression or depressive symptoms among brain tumor patients stratified by study-level characteristics

                                  No. of studies   No of patients with depression   Total number of patients   Prevalence of depression, %(95%Cl)   P for subgroup differences
  ------------------------------- ---------------- -------------------------------- -------------------------- ------------------------------------ ----------------------------
  Study Design                                                                                                                                      
  Longitudinal                    12               275                              1387                       24.0 (18.1-29.8)                     0.45
  cross-sectional                 25               696                              3131                       20.7 (16.2-25.2)                     
  Country                                                                                                                                           
  USA                             9                420                              1899                       24.3 (16.9-31.7)                     \<0.01
  UK                              7                119                              831                        14.8 (10.1-19.6)                     
  Germany                         6                132                              510                        16.6 (4.2-29.1)                      
  Italy                           5                68                               344                        21.7 (10.9-32.4)                     
  Others                          10               232                              934                        27.7 (20.4-35.1)                     
  Sample size                                                                                                                                       
  ≥100                            15               668                              3273                       19.1 (13.9-24.3)                     \<0.01
  \<100                           22               303                              1245                       23.8 (19.2-28.4)                     
  Tumor type                                                                                                                                        
  glioma                          12               340                              1908                       19.6 (15.6-23.5)                     0.09
  multiple                        25               631                              2610                       22.5 (17.4-276)                      
  Type of depression assessment                                                                                                                     
  clinician-rated                 6                172                              916                        19.1 (14.9-23.2)                     0.018
  self-rated                      27               639                              2711                       20.6 (17.2-23.1)                     
  non-depression scales           4                133                              891                        14.8 (8.5-21.00)                     

When we stratified studies by depression scales, high heterogeneity was detected (Q=273.83, P ≤0.01). Then we divided all the depression scales used by these studies into clinician-rated scales, self-rated scales and non-depression-specific scales, based on the type of depression assessment. Clinician-rated scales included DSM-IV, Hamilton Rating Scale for Depression (HDS) ≥17 \[[@R59]\], General Practitioner (GP) records \[[@R56]\], Inpatient notes \[[@R24]\] and Physical reports \[[@R36]\]. And self-rated scales included HADS-D with a cut-off ≥11 \[[@R60]\], and Patient Health Questionnaire--9 (PHQ-9) ≥10 \[[@R61], [@R62]\], BDI ≥10 \[[@R63]\], Beck depression inventory-II (BDI-II) ≥14 \[[@R64]\], Center for Epidemiologic Studies-Depression Scale (CES-D) ≥16 \[[@R65]\], HADS-D ≥8 \[[@R60]\], Zung SDS ≥41 \[[@R66]\]. Other studies which use non-depression-specific diagnostic methods were grouped as non-depression-specific scales, consist of Profiles of Mood States Short Form (POMS-SF) ≤50 \[[@R67]\], 36-Item Short Form Health Survey (SF-36) ≤60 \[[@R68]\], open ended interviews, as well as Brief Cope Scale (BCS). DSM-IV, as a clinician-rated scales, has obtained a status as the international standard for Major Depressive Disorder \[[@R2]\]. And HDS, GP records, inpatient notes and physical reports are physician-based depression symptoms rating in clinical practice. Self-rated depression scales, which are also widely applied in clinical setting, are considered as good screening tools for depressive disorder or symptoms. Non-depression-specific scales often recognize distressing emotional symptoms not restricted to depressive symptoms \[[@R69]\].

The high heterogeneity between studies could partly be explained by type of depression assessment (clinician-rated scales vs self-rated scales vs non-depression-specific scales (172/916, 19.1% \[95% CI, 14.9% to 23.2%\] vs (666/2711, 20.6% \[95% CI, 17.2% to 23.1%\] vs (133/891, 14.8% \[95% CI, 8.5% to 21.0%\]; Q = 14.96, P \< 0.01)) ([Supplementary 3E](#SD4){ref-type="supplementary-material"}). There were no significant differences between studies in which estimates was made by clinician-rated scales (Q = 2.57, P = 0.63), suggesting that variation between clinical rated tools did not explain the heterogeneity in the symptom prevalence estimates. Conversely, there were significant differences between estimates using self-rated scales (Q = 16.35, P \<0.01) and non-depression scales (Q = 202.44, P \<0.01). These results indicated that in the clinical setting, physician based assessing tools are more stable and consistent for depression diagnosis.

Secondary analysis {#s2_4}
------------------

Of the 12 longitudinal studies, we detected prevalence of depression or depressive symptoms at different time points to figure out whether there was an increased prevalence with increasing calendar year or in further analysis. Patients after diagnosis at baseline were involved in follow-up studies. Follow-up time points varied across studies, from 3 months to 12 months. 6 studies were excluded because they are in lack of available raw data on prevalence of depression or their main focus is not on the outcome and effect of depression or depressive symptoms \[[@R39], [@R50], [@R52], [@R53], [@R55], [@R70]\]. After analyzing the remaining 6 longitudinal studies \[[@R6], [@R7], [@R20], [@R40], [@R51], [@R54]\], brain tumor patients presented with a slightly higher prevalence of depression in the follow-up period (Relative Increase Ratio:1.35, 95% CI(1.04, 1.76)) (P = 0.025) (Table [3](#T3){ref-type="table"}). Sensitivity analysis for the secondary analysis revealed that Angelo's study has substantial influence on the final result \[[@R51]\]. After moving out this study, the result showed that prevalence of depression remained no change in further analysis. (Relative Increase Ratio: 1.20, 95% CI(0.91, 1.59)) (P = 0.204).

###### Secondary analysis of 6 longitudinal studies reporting prevalence estimates with increasing calendar year in further analysis

                                          Baseline                            Follow-up                           Comparison
  ---------- ------ -------------- ------ ---------- ----- ------------------ ----------- ----- ----------------- -------------------
  Hickmann   2016   BDI ≥10        3 mo   19         70    27.1(16.7, 37.6)   20          70    28.6(18.0,39.2)   1.05 (0.52,2.14)
  Litofsky   2004   SF-36 ≤60      6 mo   87         573   15.2(12.2,18.1)    42          193   21.8(15.9,27.6)   1.43 (0.96,2.14)
  Piil       2015   HADS-D ≥11     6 mo   11         28    39.3(21.2,57.4)    5           26    19.2(4.0,34.4)    0.49 (0.15,1.60)
  ANGELO     2008   Zung SDS ≥41   6 mo   7          72    9.7(2.9,16.6)      26          72    36.1(25.0,47.2)   3.71 (1.52,9.10)
  Goebel     2012   HADS-D ≥11     6 mo   9          76    11.8(4.6,19.1)     14          76    18.4(9.7,27.1)    1.56 (0.64,3.81)
  Mainio     2006   BDI ≥10        3 mo   27         77    35.1(24.4,45.7)    29          81    35.8(25.4,46.2)   1.02 (0.55, 1.88)

Publication bias {#s2_5}
----------------

Publication bias was investigated by funnel plot (Figure [3](#F3){ref-type="fig"}) and Egger test. Significant publication bias among studies was detected by visual inspection of funnel plot, and there was asymmetrical distribution of the studies indicating publication bias (Egger test P = 0.012).

![Funnel plot for the included studies that examined small study effects\
The dashed line represents 95% confidence intervals. Circles represent individual studies.](oncotarget-08-94932-g003){#F3}

DISCUSSION {#s3}
==========

This systematic review and meta-analysis involved 4518 patients with intracranial tumor from 37 observational studies and demonstrated a high prevalence of depression or depressive symptoms (overall prevalence 21.7%; 95 % CI 18.2%--25.2%). The prevalence is higher than that in normal population, which is up to 4 % of men and 8 % of women \[[@R71]\]. The reason is possibly awareness of disease state and the effect of treatment. But the prevalence is comparably lower than that in patients with diabetes and breast cancer, partly due to its rapid disease progression \[[@R72]--[@R76]\]. Brain tumor patients with depression or depressive symptoms are reported to have worse health related quality of life (HRQoL), elevated risk of suicide, more medical complications and worse survival \[[@R5], [@R20], [@R44], [@R54], [@R57]\]. Unfortunately, only part of patients with depression are properly treated \[[@R20]\]. Thus assessment of depression or depressive symptoms in patients with brain tumor is essential for clinical practitioners to improve prognosis and HRQoL. The role of depression in intracranial tumor patients should be well understood and studied to develop proper management as well.

In explaining the heterogeneity of this meta-analysis, we stratified the groups according to types of depression assessment and found no significant variation in prevalence estimate with clinician-rated depression scales. There were no significant differences between studies in which estimates was made by clinician-rated scales, suggesting that variation between clinical rated tools did not explain the heterogeneity in the symptom prevalence estimates. These results indicated that in the clinical setting, physician based assessing tools are reliable and consistent for depression diagnosis. However, self-rated scales and non-depression-specific scales varied largely in evaluating the estimate prevalence, especially self-rated scales that yielded significantly higher estimates, which could partly explain the heterogeneity \[[@R77]\].

There seems no consensus to define the best standardized scale for assessing the depression or depressive symptoms in brain tumor patients \[[@R77]\]. Therefore, how to accurately assess the prevalence of depression or depressive symptoms and distinguish it from natural reaction is very important \[[@R69]\]. In the study of the association between depression and insulin resistance, Kan et al. divided assessing tools into clinician diagnostic interviews and self-report measures, and observed higher prevalence in the latter group \[[@R78]\]. DSV-IV, HDS and other clinician diagnostic interviews, are validated and consistent in the identification of depression or depressive symptoms. And the patient-reported depression is usually discordant with clinician diagnostic scales \[[@R20]\]. The classification strategy, indeterminate cut-off point and analyzed results indicated the less accuracy and consistence of self-report measures in the diagnosis of depression. However, some self-report measures such as BDI/II, Zung SDS and HADS-D with reasonable cut-off and specific questionnaire could help to screen and assess depression prevalence among brain tumor patients, because they may save time, identify comorbid conditions even with inadequate provider knowledge of the diagnostic criteria, avoid the absence of anonymity and monitor the severity easily \[[@R69]\]. Moreover, non-depression-specific screening methods such as POMS-SF and SF-36 would be better limited into primary epidemiologic screening rather than definite diagnosis, for they recognize distressing emotional symptoms not restricted to depressive symptoms and are associated with low specificity and accuracy \[[@R77]\]. Besides, different depression scales using categorical (yes/no decisions) or dimensional assessment (determined by score or cut-off point) have different estimates of depression, contributing to the heterogeneity \[[@R79]\].

On the other hand, we also investigated correlations between depression prevalence and study characteristics depending on study design, tumor type, sample size, tumor grade, and Newcastle-Ottawa scores. No significant correlation with depression prevalence was found in study design, tumor type and Newcastle-Ottawa scores. Patients with high grade glioma show higher depression prevalence than those with low grade brain tumor. Studies of smaller sample size got an increased depression estimate, suggesting the presence of publication bias. Of the countries patients were recruited, patients from USA had a higher depression prevalence estimate than other countries. This could partly explained by the common use of self-rated assessment tools such as PHQ≥10, BDI ≥10 and CES-D ≥16 \[[@R20], [@R23], [@R37]\] and non-depression-specific scales such as POMS-SF \[[@R22]\] and SF-36 \[[@R20]\] in USA.

A secondary analysis during follow-up periods didn't show an increased prevalence of depression among brain tumor patients after the primary diagnosis. The Relative Increase Ratio in depressive symptoms 1.20, 95% CI (0.91, 1.59), which indicated no remission of depressive symptoms over time. Limited raw data for secondary analysis also indicated the lack of proper monitoring and management of co-morbid depressive symptoms for patients with brain tumor \[[@R51]\].

The study also has some limitations. Firstly, a high heterogeneity in different studies has emerged, although it could be partly explained by different tumor grade, countries and screening methods. Unexamined factors, such as the institutional culture may also play an important role in it \[[@R80]\]. Secondly, the studies included in this meta-analysis didn't allow understanding the prevalence of depression in brain tumor patients compared with depression prevalence in extracranial tumor patients. It will be better if more stratified cohort studies are conducted to compare different types of brain tumor with health control. More longitudinal studies with constant assessment and management during follow-up periods are necessary to generate more accurate analysis of depression prevalence and prognosis in further studies. Although with few evidence, it remained to be settled down that whether depression symptoms have significant impact on tumor progression and patients' survival. Diagnosis and treatment of co-morbid depression in brain tumor patients need to be addressed by more studies, and antidepressant therapy or psychotherapeutic intervention for those with co-morbid depression would lead to better life quality and oncology management \[[@R19], [@R20]\].

MATERIALS AND METHODS {#s4}
=====================

Search strategy and inclusion criteria {#s4_1}
--------------------------------------

We searched on PUBMED, PsycINFO and Cochrane library for all peer-reviewed English-language literature from January 1981 through October 2016. The key words used for the database search were: "brain tumor," OR "intracranial tumors" OR "carcinoma, intracranial," AND "depression," OR "depressive symptoms," OR "depressive disorders," and the individual corresponding free terms to find more relevant studies (full details of the search strategy are provided in the [Supplementary 1](#SD2){ref-type="supplementary-material"}). We also searched reviews and meta-analyses to identify studies that may be missed in the former literature searches. Furthermore, all citations in the retrieved articles were obtained and reviewed in full text to search for additional eligible studies \[[@R15]\].

The strategies we used for quality assessment and design protocol is Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-P) 2015 guideline \[[@R16]\] ([Supplementary 6](#SD6){ref-type="supplementary-material"}), which consists of a detailed, well-described checklist for administrative information, introduction, and methods to promote accountability, research integrity, and transparency of the meta-analysis. In addition, we used a modified version of the Newcastle-Ottawa Scale to assess the quality of studies included in systematic reviews and meta-analysis \[[@R17]\]. This scale assessed the quality of studies in the following parts: sample representativeness, sample size, comparability between respondents and non-respondents, outcome of depression diagnosis, and statistical quality (full details in the [Supplementary 2](#SD3){ref-type="supplementary-material"}). Studies with scores ≥3 points were assessed as low risk of bias, and with scores \<3 were in high risk of bias.

All studies published were included if 1) they could be defined as an observational study or a randomized controlled trial which involved patients with brain tumor; 2) All depression screening scales were accepted in the analysis; 3) The diagnosis of brain tumor was according to the guideline of the 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) in the analysis \[[@R18]\]. We excluded studies without full reports; studies included \<20 patients; non--English-language studies; case reports. Only the most informative and/or the recent one will be included if they came from the same authors or the same patient group used in multiple reports.

Two investigators (J. Huang and Chao Zeng) independently performed a systematic review of all identified citations. Papers focusing on selected patients but potentially reporting data about depression were selected for full-text review and checked for eligibility.

Data extraction and quality assessment of included studies {#s4_2}
----------------------------------------------------------

A standardized data extraction was used by two investigators (J. Huang and Chao Zeng) and checked by the other authors. Any discrepancies were settled by consensus. The following data was abstracted from all included studies: study design, year, country, patients involved, tumor grade, education levels, diagnostic or screening method and prevalence. The demographic and clinical characteristics of the publications included were summarized in Table. When more than one point prevalence estimate of depression would have been recorded in longitudinal studies within the year, the overall period prevalence for the time period was used. It should be also noted that in 10 studies, data were recorded separately for high-grade glioma and low-grade glioma clearly on depression prevalence \[[@R4], [@R6], [@R7], [@R14], [@R19]--[@R24]\].

Statistical analysis {#s4_3}
--------------------

The prevalence estimates of depression co-morbidity was calculated by random-effects meta-analysis that accounted for between- study heterogeneity \[[@R15], [@R25], [@R26]\]. Statistical heterogeneity among studies was assessed using the χ2 test on Cochran's Q statistic and by calculating I^2^ \[[@R27]\]. I^2^ values of 25%, 50%, and 75% were defined as low, moderate, and high heterogeneity separately \[[@R28]\]. An I^2^ value greater or equal than 50% indicated considerable levels of heterogeneity \[[@R27], [@R28]\]. We also conducted a sensitivity analysis by serially excluding each study and repeating the meta-analysis to evaluate whether the results were affected statistically significantly by individual studies. Publication bias was evaluated by using funnel plots and the Egger test \[[@R29], [@R30]\]. Summary estimates of depression for patients with brain tumor were analyzed using Strata software (version 12.1; Stata Corp, College Station, TX). Forest plots were constructed as well. In all analyses, p value \<0.05 was considered statistically significant. Where appropriate, if information was available, we compared results from different studies separately based on their characteristics (study design, country, tumor type, sample size, tumor type, tumor grade and diagnostic accuracy) using stratified meta-analysis and subgroup analysis \[[@R31], [@R32]\].
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BDI

:   Beck Depression Inventory

HADS-D

:   Depression Subscale of Hospital Anxiety and Depression Scale

DSM-IV

:   Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition

PHQ-9

:   Patient Health Questionnaire--9

HDS

:   Hamilton Rating Scale for Depression

SF-36

:   36-Item Short Form Health Survey

BDI-II

:   Beck Depression Inventory-II

CES-D

:   Center for Epidemiologic Studies-Depression Scale

BCS

:   Brief Cope Scale

Zung SDS

:   Zung Self-rating Depression Scale

POMS-SF

:   Profiles of Mood States Short Form

GP

:   General Practitioner (family physician)

SF-36

:   36-Item Short Form Health Survey

NR

:   not applicable
